Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Association between CYP2C19 polymorphism and depressive symptoms.

Sim SC, Nordin L, Andersson TM, Virding S, Olsson M, Pedersen NL, Ingelman-Sundberg M.

Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1160-6. doi: 10.1002/ajmg.b.31081.

PMID:
20468063
2.

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.

Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S, Uher R, Gunasinghe C, Gray J, Campbell D, Hauser J, Maier W, Marusic A, Rietschel M, Perez J, Giovannini C, Mors O, Mendlewicz J, McGuffin P, Farmer AE, Ingelman-Sundberg M, Craig IW, Aitchison KJ.

J Psychopharmacol. 2012 Mar;26(3):398-407. doi: 10.1177/0269881111414451. Epub 2011 Sep 17.

PMID:
21926427
3.

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.

Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, Chow MS.

J Clin Psychopharmacol. 2006 Aug;26(4):367-72. Erratum in: J Clin Psychopharmacol. 2006 Oct;26(5):523. Wing, Yun-Kowk [corrected to Wing, Yun-Kwok].

PMID:
16855453
4.

CYP2C19 variation and citalopram response.

Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM.

Pharmacogenet Genomics. 2011 Jan;21(1):1-9.

5.

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M.

Clin Pharmacol Ther. 2006 Jan;79(1):103-13.

PMID:
16413245
6.

Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.

Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH.

Drug Metab Dispos. 2003 Oct;31(10):1255-9.

7.

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH.

Clin Pharmacol Ther. 2001 Jul;70(1):42-7.

PMID:
11452243
8.

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL.

Pharmacogenomics. 2010 Apr;11(4):537-46. doi: 10.2217/pgs.09.168.

PMID:
20350136
9.

Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.

Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG.

Fundam Clin Pharmacol. 2007 Aug;21(4):419-26.

PMID:
17635181
10.

CYP2C19 polymorphism affects personality traits of Japanese females.

Ishii G, Suzuki A, Oshino S, Shiraishi H, Otani K.

Neurosci Lett. 2007 Jan 3;411(1):77-80. Epub 2006 Oct 18.

PMID:
17052843
11.

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.

Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I.

Hum Psychopharmacol. 2013 Sep;28(5):516-22. doi: 10.1002/hup.2340.

PMID:
24014145
12.

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients.

Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D.

Int Clin Psychopharmacol. 2009 Sep;24(5):250-6. doi: 10.1097/YIC.0b013e32832e5b0d.

PMID:
19593158
13.

Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.

Kobayashi K, Morita J, Chiba K, Wanibuchi A, Kimura M, Irie S, Urae A, Ishizaki T.

Pharmacogenetics. 2004 Aug;14(8):549-56.

PMID:
15284537
14.

Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.

Lei HP, Wang G, Wang LS, Ou-yang DS, Chen H, Li Q, Zhang W, Tan ZR, Fan L, He YJ, Zhou HH.

Ann Pharmacother. 2009 Apr;43(4):726-31. doi: 10.1345/aph.1L537. Epub 2009 Mar 18.

PMID:
19299322
15.

[Cytochrome P450 2C19 gene polymorphism in 104 Chinese Zang volunteers].

Ding HW, Dong WZ, Jiang ZG, Ma X.

Yi Chuan. 2004 Mar;26(2):151-4. Chinese.

PMID:
15639978
16.

Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response.

Yadav SS, Ruwali M, Shah PP, Mathur N, Singh RL, Pant MC, Parmar D.

Mutat Res. 2008 Sep 26;644(1-2):31-7. doi: 10.1016/j.mrfmmm.2008.06.010. Epub 2008 Jul 3.

PMID:
18644391
17.

Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.

Isaza C, Henao J, Martínez JH, Sepúlveda Arias JC, Beltrán L.

BMC Clin Pharmacol. 2007 Jul 11;7:6.

18.

Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.

Vicente J, González-Andrade F, Soriano A, Fanlo A, Martínez-Jarreta B, Sinués B.

Mol Biol Rep. 2014 Mar;41(3):1267-72. doi: 10.1007/s11033-013-2971-y. Epub 2014 Jan 16.

PMID:
24430292
19.

Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.

Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp SO, Roots I, Brockmöller J.

Clin Pharmacol Ther. 1999 Aug;66(2):185-92.

PMID:
10460072
20.

Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.

Zendehdel N, Biramijamal F, Hossein-Nezhad A, Zendehdel N, Sarie H, Doughaiemoghaddam M, Pourshams A.

Arch Iran Med. 2010 Sep;13(5):406-12. doi: 010135/AIM.007.

Supplemental Content

Support Center